83 related articles for article (PubMed ID: 22310342)
1. Borderline tumors of the ovary: clinical course and prognostic factors.
Ewald-Riegler N; du Bois O; Fisseler-Eckhoff A; Kommoss F; Harter P; Traut A; Hils R; du Bois A
Onkologie; 2012; 35(1-2):28-33. PubMed ID: 22310342
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
Sornsukolrat S; Tuipae S
J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
[TBL] [Abstract][Full Text] [Related]
3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
4. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
5. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors and treatment for advanced-stage borderline ovarian tumors].
Morice P; Camatte S; Rouzier R; Pautier P; Atallah D; Pomel C; Lhomme C; Duvillard P; Castaigne D
J Gynecol Obstet Biol Reprod (Paris); 2002 Nov; 31(7):623-8. PubMed ID: 12457134
[TBL] [Abstract][Full Text] [Related]
8. Recurrence and prognostic factors in borderline ovarian tumors.
Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
[TBL] [Abstract][Full Text] [Related]
9. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
Plett H; Harter P; Ataseven B; Heitz F; Prader S; Schneider S; Heikaus S; Fisseler-Eckhoff A; Kommoss F; Lax SF; Staebler A; Traut A; du Bois A
Gynecol Oncol; 2020 May; 157(2):411-417. PubMed ID: 32115229
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
Suh-Burgmann E
Gynecol Oncol; 2006 Dec; 103(3):841-7. PubMed ID: 16793124
[TBL] [Abstract][Full Text] [Related]
11. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary.
Park JY; Jin KL; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2012 Apr; 125(1):80-6. PubMed ID: 22210469
[TBL] [Abstract][Full Text] [Related]
12. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
[TBL] [Abstract][Full Text] [Related]
13. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
14. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
Anfinan N; Sait K; Ghatage P; Nation J; Chu P
Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
[TBL] [Abstract][Full Text] [Related]
15. Prognosis and management of borderline tumours of the ovary.
Tropé C; Kaern J
Curr Opin Obstet Gynecol; 1996 Feb; 8(1):12-6. PubMed ID: 8777251
[TBL] [Abstract][Full Text] [Related]
16. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
Classe JM; Jaffre I; Frenel JS; Bordes V; Dejode M; Dravet F; Ferron G; Marchal F; Rigaud DB; Loussouarn D; Campion L
Eur J Surg Oncol; 2011 Nov; 37(11):971-7. PubMed ID: 21944959
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
20. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.
Earle CC; Schrag D; Neville BA; Yabroff KR; Topor M; Fahey A; Trimble EL; Bodurka DC; Bristow RE; Carney M; Warren JL
J Natl Cancer Inst; 2006 Feb; 98(3):172-80. PubMed ID: 16449677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
